Navigation Links
Canandian Firm Announces Positive Results from Anti- Cervical Cancer Drug Trials

The Helix BioPharma Corporation has announced positive results from its phase II clinical study of its Topical Interferon Alpha-2b in women with human papilloma virus (HPV)-induced low-grade cervical lesions.//

Human papilloma viruses (HPVs) are a large group of related viruses. They play a part in the development of cervical epithelial cancers. HPV is also associated with skin, oral and anal cancers.

Helix BioPharma Corporation is a Canada-based firm specializing in cancer therapies.

It says that its study showed a clinically efficacious response to the topical interferon treatment in nearly half of the treated patients. In addition, the product demonstrated an excellent safety profile, with no significant adverse side-effects.

Prof. Dr. Achim Schneider, a renowned expert in the field of cervical cancer and Director of the Department of Gynaecology at the Charité University Hospital in Berlin, said, . "Helix's product shows real promise as a practical and effective pharmaceutical means of preventing cervical cancer development in women affected by HPV-induced cervical lesions."

Twenty women received Topical Interferon Alpha-2b, self-administered intravaginally three times per week for a period of 6 weeks with a follow-up evaluation at 12 weeks, compared with 21 separately studied women who received no treatment whatsoever over the same study period.

Nearly half (46.7%) of the women in the treated population had their abnormal Pap smears revert to normal during the 12 week period, compared with only 15.8% of the untreated women (i.e., nearly a three-fold improvement).

In a PAP test cells from the cervix are collected for examination under a microscope. It is used to detect changes that may be cancer or may lead to cancer. It is named after George Papanicolaou, an American anatomist. "We are very pleased to have achieved this milestone in the continuing development of our Topical Inte rferon Alpha-2b product candidate," said John Docherty, Helix's Vice President of Corporate Development.

"Helix is committed to further advancing its clinical development program for this extremely prevalent condition, in order to bring this product to market as expeditiously as possible."

Interferon alpha-2b is an immune system modulator that is active against variety of HPV-induced lesions. Immune modulation is a new emerging field in the medical treatment of viral infections. It works by introducing an agent into the body that boosts specific areas of the immune system.

Interferon alpha-2b is thought to function by triggering an antiviral response within infected cells and by mobilizing the body's natural immune system to destroy the infected cells.

Helix's Topical Interferon Alpha-2b is expected to offer a safe, discreet, self-administered and pain-free therapy.
GP
'"/>




Related medicine news :

1. Ramdoss Announces Introduction of RCH-II
2. Britain Announces Third Transfusion Related Mad Cow Case
3. Tibet Announces the Dalai Lama’s Tour of South Americ
4. Indian PM Announces Of Setting Up India Study Center At Tashkent
5. PowderMed Announces Needle-Less Flu Vaccine
6. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
7. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
8. Australian Government Announces Survey To Tackle Childhood Obesity
9. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
10. Apollo Announces Research on Indian Cardiac Epidemic
11. Government Announces Steps To Promote Ayurvedic Medicine
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg ... Legal Elite. The attorneys chosen by their peers for this recognition are considered among ... Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite Hall ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, ... economy by obtaining investment capital for emerging technology companies. SCP has delivered ... already resulted in more than a million dollars of capital investment for five ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
Breaking Medicine Technology: